In last trading session, Heron Therapeutics Inc. (NASDAQ:HRTX) saw 3.31 million shares changing hands with its beta currently measuring 1.11. Company’s recent per share price level of $4.33 trading at -$0.34 or -7.28% at ring of the bell on the day assigns it a market valuation of $463.40M. That closing price of HRTX’s stock is at a discount of -197.69% from its 52-week high price of $12.89 and is indicating a premium of 49.42% from its 52-week low price of $2.19. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.63 million shares which gives us an average trading volume of 3.39 million if we extend that period to 3-months.
For Heron Therapeutics Inc. (HRTX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.5 in the current quarter.
Heron Therapeutics Inc. (NASDAQ:HRTX) trade information
Upright in the red during last session for losing -7.28%, in the last five days HRTX remained trading in the red while hitting it’s week-highest on Friday, 09/16/22 when the stock touched $4.33 price level, adding 15.1% to its value on the day. Heron Therapeutics Inc.’s shares saw a change of -52.57% in year-to-date performance and have moved -6.88% in past 5-day. Heron Therapeutics Inc. (NASDAQ:HRTX) showed a performance of -2.48% in past 30-days. Number of shares sold short was 40.18 million shares which calculate 13.42 days to cover the short interests.
Heron Therapeutics Inc. (HRTX) estimates and forecasts
Statistics highlight that Heron Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -21.70% of value to its shares in past 6 months, showing an annual growth rate of 21.43% while that of industry is 11.70. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 19.40% in the current quarter and calculating 9.80% increase in the next quarter. This year revenue growth is estimated to rise 23.60% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $24.31 million for the same. And 4 analysts are in estimates of company making revenue of $27.53 million in the next quarter that will end on Sep 2022. Company posted $22.44 million and $23.23 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 8.30% while estimating it to be 18.50% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 13.30% during past 5 years. In 2022, company’s earnings growth rate is likely to be around 10.50% while estimates for its earnings growth in next 5 years are of 47.50%.
Heron Therapeutics Inc. is more likely to be releasing its next quarterly report between November 01 and November 07 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Heron Therapeutics Inc. (NASDAQ:HRTX)’s Major holders
Insiders are in possession of 0.24% of company’s total shares while institution are holding 118.79 percent of that, with stock having share float percentage of 119.08%. Investors also watch the number of corporate investors in a company very closely, which is 118.79% institutions for Heron Therapeutics Inc. that are currently holding shares of the company. State Street Corporation is the top institutional holder at HRTX for having 12.92 million shares of worth $73.92 million. And as of Mar 30, 2022, it was holding 12.61% of the company’s outstanding shares.
The second largest institutional holder is Franklin Resources, Inc., which was holding about 11.88 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 11.59% of outstanding shares, having a total worth of $67.95 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and JP Morgan Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 14.12 million shares of worth $39.4 million or 13.78% of the total outstanding shares. The later fund manager was in possession of 3.57 million shares on Mar 30, 2022, making its stake of worth around $20.44 million in the company or a holder of 3.49% of company’s stock.